56713Sun Yet-Sen Memorial Hospital, Sun Yet-Sen University, Guangzhou, China.
302944South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211041454. doi: 10.1177/15330338211041454.
The apoptotic and cytotoxic effects of arsenic trioxide (ATO) makes it a potentially suitable agent for the treatment of patients with neuroblastoma with poor prognosis; therefore, we try to evaluate the effectiveness and safety of ATO combined with reinduction/induction chemotherapy in children with recurrent/refractory or newly diagnosed stage 4 neuroblastoma. Retrospective analysis was performed on seven pediatric patients with recurrent /refractory or newly diagnosed stage 4 neuroblastoma treated with traditional reinduction/induction chemotherapy combined with ATO. A total of 7 patients were treated synchronously with ATO and chemotherapy for up to nine courses; all patients received conventional chemotherapy plus a 0.16 mg/kg/day dose of intravenous ATO during reinduction/induction chemotherapy. Treatment was effective in five patients and ineffective in the other two patients. The overall response rate was 71.43% (5 of 7). The side effects of the ATO combination were minor, whereby only treatment in one patient was terminated at the sixth course due to a prolonged QT interval (0.51 s), which returned to normal after symptomatic treatment. ATO can be safely and effectively combined with chemotherapy drugs as a potential alternative means of treatment for high-risk stage 4 neuroblastoma, and we have observed that ATO can restore the sensitivity of chemotherapy in some patients who were resistant to previous chemotherapy. Further investigations and clinical data are required to confirm these observations.
三氧化二砷（ATO）的凋亡和细胞毒性作用使其成为治疗预后不良的神经母细胞瘤患者的潜在合适药物；因此，我们尝试评估 ATO 联合再诱导/诱导化疗治疗复发性/难治性或新诊断的 4 期神经母细胞瘤患儿的疗效和安全性。
对 7 例接受传统再诱导/诱导化疗联合 ATO 治疗的复发性/难治性或新诊断的 4 期神经母细胞瘤儿科患者进行回顾性分析。7 例患者同步接受 ATO 和化疗治疗，共 9 个疗程；所有患者在再诱导/诱导化疗期间均接受常规化疗和 0.16mg/kg/天剂量的静脉 ATO。5 例患者治疗有效，2 例患者无效。总的缓解率为 71.43%（5/7）。ATO 联合的副作用较小，只有 1 例患者在第 6 个疗程时因 QT 间期延长（0.51s）而终止治疗，经对症治疗后恢复正常。ATO 可与化疗药物安全有效地联合作为高危 4 期神经母细胞瘤的潜在替代治疗方法，我们观察到 ATO 可恢复对先前化疗耐药的一些患者对化疗的敏感性。需要进一步的研究和临床数据来证实这些观察结果。
